Company / Free Cash Flow
Xeris Biopharma Holdings, Inc. Free Cash Flow History
FY2020-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$96.6M
FY2021
5-year range
-$96.6M / -$96.6M
FY2020-FY2021
Trend
-19.4%
vs FY2020
Sector context
#107 of 194
Health Care
What the data says
At -$97M, Xeris Biopharma Holdings, Inc.'s free cash flow ranks #107 of 194 in the Health Care sector.
Based on SEC 10-K filings.
-$97M in FY2021.
Health Care sector context is included.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#107 of 194 in Health CareTop 55% of 194This company -$96.6M Sector average $470.6M
▼
-120.5% below sector average
Key checks
Key Insights
- In FY2021, free cash flow decreased 19.4% year-over-year.
- Ranks #107 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.26 (distress zone, below 1.8 threshold)
- Negative profit margin: -27.0%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | -$96.6M | -19.4% |
| FY2020 | -$80.9M | - |
As of FY2021 · SEC 10-K · Updated Jun 30, 2026